RT Journal Article
SR Electronic
T1 Potential spreading risks and disinfection challenges of medical wastewater by the presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral RNA in septic tanks of fangcang hospital
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.28.20083832
DO 10.1101/2020.04.28.20083832
A1 Zhang, Dayi
A1 Ling, Haibo
A1 Huang, Xia
A1 Li, Jing
A1 Li, Weiwei
A1 Yi, Chuan
A1 Zhang, Ting
A1 Jiang, Yongzhong
A1 He, Yuning
A1 Deng, Songqiang
A1 Zhang, Xian
A1 Liu, Yi
A1 Li, Guanghe
A1 Qu, Jiuhui
YR 2020
UL http://medrxiv.org/content/early/2020/05/14/2020.04.28.20083832.abstract
AB The outbreak of coronavirus infectious disease-2019 (COVID-19) pneumonia raises the concerns of effective deactivation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in medical wastewater by disinfectants. In this study, we evaluated the presence of SARS-CoV-2 viral RNA in septic tanks of Wuchang Fangcang Hospital and found the high level of (0.05-1.87)×104 copies/L after disinfection with sodium hypochlorite. Embedded viruses in stool particles might be released in septic tanks, behaving as a source of SARS-CoV-2 and potentially contributing to its spread through drainage pipelines. Current recommended disinfection strategy (free chlorine above 6.5 mg/L after 1.5-hour contact) needs to be reevaluated to completely remove SARS-CoV-2 viral RNA in non-centralized disinfection system and effectively deactivate SARS-CoV-2. The effluents showed negative results for SARS-CoV-2 viral RNA when overdosed with sodium hypochlorite but had high a level of disinfection by-product residuals, possessing significant ecological risks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in the study are available from the corresponding author by request.